Combined hepatocellular carcinoma and cholangiocarcinoma
MONDO:0044791A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed. This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver. The prognosis of this tumor is poor.
Also known as: carcinoma of liver and intrahepatic biliary tract, liver and intrahepatic biliary tract carcinoma, Cholangiohepatoma, Hepatocholangiocarcinoma, Mixed hepatocellular cholangiocarcinoma, carcinoma of the liver and intrahepatic biliary tract, combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer), combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma)
2972 clinical trials for this condition and its sub-types, 8 tagged with Combined hepatocellular carcinoma and cholangiocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail targets rare liver cancer in 29-Patient trial
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…
Phase 2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to stop rare liver cancer from coming back
Disease control Not yet recruitingThis study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can prevent a rare mixed liver cancer from returning after surgery. About 75 adults who had their tumor completely removed but are at medium-to-high risk of recurrence w…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC